ATLANTA, Oct. 16 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based, publicly traded biopharmaceutical company specializing in the prevention and treatment of infectious diseases, presented data on their AIDS vaccine (trial HVTN 065) at the AIDS Vaccine 2008 conference, on October 15 in Cape Town, South Africa. This conference comes at an exciting time for GeoVax, which is preparing to enter Phase 2 trials for its vaccine.
The presentation, titled "Two HIV DNA Primes Maximize T Cell Responses Induced by the GeoVax DNA/MVA Vaccine Regimen Administered to Healthy Seronegative Adults (HVTN 065)," was given by Dr. Paul A. Goepfert, M.D., Associate Professor, Division of Infectious Diseases, Department of Medicine, University of Alabama. Dr. Goepfert is the HVTN 065 Protocol Team chair. The trial results reveal the GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate anti-HIV/AIDS immune responses) at both low (1/10th) dose and full doses. Other highlights included:
-- GeoVax vaccines were well tolerated with no or mild local and systemic reactions in the majority of trial participants.
-- 80 percent of both the low and full dose trial participants responded to the vaccine which stimulated anti-HIV T-cell (white blood cell) and antibody responses.
-- More volunteers had antibody responses to the full dose than to the 1/10th dose vaccine, whereas response rates for T cells were similar for the 1/10th and full dose.
-- Two DNA primes were more effective than one DNA prime or no DNA primes at eliciting T cell responses.
-- The 2nd MVA vaccination positively increased CD8 T cell and antibody responses.
"As the entire world tries to find a solution for the HIV/AIDS crisis,
GeoVax, a front runner in the search for an effective vaccine, is on the
verge of entering Phase 2 trials," said Bob McNally, CEO and President of
GeoVax Labs, Inc. "The AIDS Vaccine 2008 conference is a
|SOURCE GeoVax Labs, Inc.|
Copyright©2008 PR Newswire.
All rights reserved